Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 vixarelimab versus placebo in idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease
MOH_2023-05-07_012607Phase 2Recruiting
- Sponsor
- Roche
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vixarelimab in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) (4 cohorts), sponsored by Roche. Primary endpoint: Primary endpoints not reported. Started Apr 2023; status: recruiting.
02
Drugs
vixarelimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on MOH_2023-05-07_012607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-07_012607.